Medicare Benefits Schedule - Item 73445

Characterisation of a variant or variants in a panel of at least 25 genes using DNA and RNA, requested by a specialist or consultant physician, to determine the diagnosis, prognosis and/or management of a patient presenting with a clinically suspected haematological malignancy of myeloid origin

Applicable once per diagnostic episode, at diagnosis, disease progression or relapse

Fee: $1,100.00 Benefit: 75% = $825.00 85% = $1,001.30

(See para PN.7.14 of explanatory notes to this Category)

• Previous - Item 73444
• Next - Item 73446

Testing should include, but not be restricted to, genes described in the current World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms or other appropriate international guidelines.

Related Items: 73445 73446 73447 73448